Symbols / GANX Stock $1.97 +4.23% Gain Therapeutics, Inc.

Healthcare • Biotechnology • United States • NGM
GANX (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Gene Mack M.B.A.
Exch · Country NGM · United States
Market Cap 83.70M
Enterprise Value 63.11M
Income -20.16M
Sales —
FCF (ttm) -10.50M
Book/sh 0.44
Cash/sh 0.49
Employees 20
Insider 10d —
IPO Mar 19, 2021
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -3.16
PEG —
P/S —
P/B 4.47
P/C —
EV/EBITDA -3.38
EV/Sales —
Quick Ratio 6.46
Current Ratio 6.63
Debt/Eq 3.94
LT Debt/Eq —
EPS (ttm) -0.61
EPS next Y -0.62
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-03-26
Earnings (prior) 2026-03-26
ROA -67.00%
ROE -155.66%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 42.49M
Shs Float 40.90M
Insider Own 2.31%
Instit Own 19.08%
Short Float 8.02%
Short Ratio 4.68
Short Interest 3.33M
52W High 4.34
vs 52W High -54.61%
52W Low 1.41
vs 52W Low 39.72%
Beta 0.11
Impl. Vol. 1.60%
Rel Volume 0.97
Avg Volume 687.25K
Volume 664.74K
Target (mean) $7.60
Tgt Median $8.00
Tgt Low $5.00
Tgt High $10.00
# Analysts 5
Recom None
Prev Close $1.89
Price $1.97
Change 4.23%
About

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. Its lead drug candidate is GT-02287, which is currently in a Phase 1b study for the treatment of Parkinson's disease with or without a GBA1 mutation. The company has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of dementia with Lewy bodies, Alzheimer's disease, and Gaucher's disease, lysosomal storage disorders, metabolic disorders, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is based in Bethesda, Maryland.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$7.60
Mean price target
2. Current target
$1.97
Latest analyst target
3. DCF / Fair value
$-4.45
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.97
Low
$5.00
High
$10.00
Mean
$7.60

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-12-19 reit HC Wainwright & Co. Buy → Buy $8
2025-10-15 reit BTIG Buy → Buy $9
2025-10-13 reit HC Wainwright & Co. Buy → Buy $8
2025-10-07 main Maxim Group Buy → Buy $7
2025-09-08 reit BTIG Buy → Buy $9
2025-08-13 main Roth Capital Buy → Buy $6
2025-07-03 reit HC Wainwright & Co. Buy → Buy $8
2025-05-19 reit HC Wainwright & Co. Buy → Buy $8
2025-03-28 main Chardan Capital Buy → Buy $6
2025-03-17 reit HC Wainwright & Co. Buy → Buy $8
2025-03-07 init Scotiabank — → Sector Outperform $12
2024-12-24 main Roth MKM Buy → Buy $7
2024-12-05 init Roth MKM — → Buy $7
2024-11-25 reit HC Wainwright & Co. Buy → Buy $8
2024-10-09 reit HC Wainwright & Co. Buy → Buy $8
2024-10-01 reit HC Wainwright & Co. Buy → Buy $8
2024-09-03 reit HC Wainwright & Co. Buy → Buy $8
2024-08-09 main Chardan Capital Buy → Buy $6
2024-07-11 reit HC Wainwright & Co. Buy → Buy $8
2024-07-02 main HC Wainwright & Co. Buy → Buy $8
News
RSS: Latest GANX news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2024-08-09 ISLAM KHALID Officer and Director — 50,000 $1.00 $49,940
2024-08-09 MACK GENE C Chief Executive Officer — 14,400 $1.01 $14,544
2024-07-01 RICHMAN ERIC I. Director — 17,000 $1.21 $20,670
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
-100.00%
0.06
-60.62%
0.14
Operating Revenue
0.00
0.00
-100.00%
0.06
-58.40%
0.13
Operating Expense
18.71
-8.06%
20.35
-8.78%
22.31
+24.51%
17.92
Research And Development
10.21
-5.36%
10.79
-6.33%
11.52
+37.52%
8.38
Selling General And Administration
8.50
-11.11%
9.56
-11.38%
10.79
+13.08%
9.54
General And Administrative Expense
8.50
-11.11%
9.56
-11.38%
10.79
+13.08%
9.54
Other Gand A
8.50
-11.11%
9.56
-11.38%
10.79
+13.08%
9.54
Total Expenses
18.71
-8.06%
20.35
-8.78%
22.31
+24.51%
17.92
Operating Income
-18.71
+8.06%
-20.35
+8.55%
-22.25
-25.18%
-17.78
Total Operating Income As Reported
-18.71
+8.06%
-20.35
+8.55%
-22.25
-25.18%
-17.78
EBITDA
-18.62
+8.14%
-20.27
+8.58%
-22.17
-25.16%
-17.71
Normalized EBITDA
-17.78
+12.77%
-20.39
+6.23%
-21.74
-23.41%
-17.62
Reconciled Depreciation
0.09
+11.86%
0.08
+0.59%
0.08
+30.25%
0.06
EBIT
-18.71
+8.06%
-20.35
+8.55%
-22.25
-25.18%
-17.78
Total Unusual Items
-0.83
-799.86%
0.12
+127.74%
-0.43
-346.89%
-0.10
Total Unusual Items Excluding Goodwill
-0.83
-799.86%
0.12
+127.74%
-0.43
-346.89%
-0.10
Net Income
-20.16
+1.23%
-20.41
+8.34%
-22.27
-26.59%
-17.59
Pretax Income
-19.30
+2.89%
-19.87
+10.43%
-22.19
-26.81%
-17.50
Net Non Operating Interest Income Expense
0.24
-31.56%
0.36
-27.75%
0.49
+31.67%
0.38
Net Interest Income
0.24
-31.56%
0.36
-27.75%
0.49
+31.67%
0.38
Interest Income Non Operating
0.24
-31.56%
0.36
-27.75%
0.49
+31.67%
0.38
Interest Income
0.24
-31.56%
0.36
-27.75%
0.49
+31.67%
0.38
Other Income Expense
-0.83
-799.86%
0.12
+127.74%
-0.43
-346.89%
-0.10
Gain On Sale Of Security
-0.83
-799.86%
0.12
+127.74%
-0.43
-346.89%
-0.10
Tax Provision
0.86
+60.41%
0.54
+577.16%
0.08
-14.74%
0.09
Tax Rate For Calcs
0.00
+0.00%
0.00
+0.00%
0.00
+3862.26%
0.00
Tax Effect Of Unusual Items
-0.18
-799.86%
0.03
+127.74%
-0.09
-17607.00%
-0.00
Net Income Including Noncontrolling Interests
-20.16
+1.23%
-20.41
+8.34%
-22.27
-26.59%
-17.59
Net Income From Continuing Operation Net Minority Interest
-20.16
+1.23%
-20.41
+8.34%
-22.27
-26.59%
-17.59
Net Income From Continuing And Discontinued Operation
-20.16
+1.23%
-20.41
+8.34%
-22.27
-26.59%
-17.59
Net Income Continuous Operations
-20.16
+1.23%
-20.41
+8.34%
-22.27
-26.59%
-17.59
Normalized Income
-19.50
+4.89%
-20.51
+6.49%
-21.93
-25.34%
-17.50
Net Income Common Stockholders
-20.16
+1.23%
-20.41
+8.34%
-22.27
-26.59%
-17.59
Diluted EPS
—
-0.89
+47.95%
-1.71
-15.54%
-1.48
Basic EPS
—
-0.89
+47.95%
-1.71
-15.54%
-1.48
Basic Average Shares
—
22.88
+75.86%
13.01
+9.49%
11.88
Diluted Average Shares
—
22.88
+75.86%
13.01
+9.49%
11.88
Diluted NI Availto Com Stockholders
-20.16
+1.23%
-20.41
+8.34%
-22.27
-26.59%
-17.59
Total Other Finance Cost
—
—
—
-0.38
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
22.82
+88.22%
12.12
-34.85%
18.61
-22.78%
24.10
Current Assets
22.24
+91.66%
11.60
-34.74%
17.78
-15.71%
21.09
Cash Cash Equivalents And Short Term Investments
20.84
+100.63%
10.39
-38.16%
16.79
-16.60%
20.14
Cash And Cash Equivalents
20.84
+100.63%
10.39
-11.95%
11.79
+61.32%
7.31
Cash Equivalents
11.06
+133.09%
4.75
-29.88%
6.77
+53.76%
4.40
Cash Financial
9.78
+73.33%
5.64
+12.20%
5.03
+72.75%
2.91
Other Short Term Investments
—
0.00
-100.00%
5.00
-61.02%
12.83
Receivables
0.80
+4.82%
0.77
+215.68%
0.24
+26.80%
0.19
Accounts Receivable
—
—
—
—
Other Receivables
0.62
+25.94%
0.49
—
0.09
Taxes Receivable
0.18
-33.71%
0.27
+11.75%
0.24
+133.52%
0.10
Prepaid Assets
0.60
+32.38%
0.45
-39.21%
0.74
-2.60%
0.76
Current Deferred Assets
—
—
—
—
Restricted Cash
—
—
—
—
Total Non Current Assets
0.58
+11.59%
0.52
-37.22%
0.83
-72.39%
3.01
Net PPE
0.41
+26.50%
0.32
-44.75%
0.59
-27.25%
0.80
Gross PPE
0.59
+32.70%
0.45
-34.11%
0.68
-20.95%
0.86
Accumulated Depreciation
-0.18
-48.97%
-0.12
-32.93%
-0.09
-74.01%
-0.05
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
0.18
+11.10%
0.16
+8.82%
0.15
+13.40%
0.13
Other Properties
0.38
+48.50%
0.26
-48.64%
0.50
-28.64%
0.70
Leases
0.04
+14.18%
0.03
-6.99%
0.03
+8.13%
0.03
Goodwill And Other Intangible Assets
0.10
-23.41%
0.13
-30.57%
0.19
-9.62%
0.21
Other Intangible Assets
0.10
-23.41%
0.13
-30.57%
0.19
-9.62%
0.21
Investments And Advances
—
—
0.00
-100.00%
1.94
Non Current Prepaid Assets
—
—
—
—
Other Non Current Assets
0.07
+9.70%
0.06
+22.91%
0.05
+7.42%
0.05
Total Liabilities Net Minority Interest
4.25
-11.08%
4.78
-20.67%
6.03
+15.54%
5.22
Current Liabilities
3.35
-14.29%
3.91
-20.98%
4.95
+19.99%
4.13
Payables And Accrued Expenses
3.09
-8.34%
3.37
-1.77%
3.43
-5.38%
3.63
Payables
0.99
-15.54%
1.18
-30.33%
1.69
-10.39%
1.88
Accounts Payable
0.83
-12.81%
0.95
-28.26%
1.32
-18.89%
1.63
Other Payable
0.17
-26.79%
0.23
-37.74%
0.37
+43.44%
0.26
Current Accrued Expenses
2.10
-4.48%
2.19
+25.87%
1.74
+0.02%
1.74
Employee Benefits
0.39
-11.97%
0.44
+44.29%
0.31
+95.11%
0.16
Current Debt And Capital Lease Obligation
0.22
-18.57%
0.27
-22.21%
0.35
+3.34%
0.34
Current Debt
0.10
-8.45%
0.11
-7.26%
0.12
+9.86%
0.11
Other Current Borrowings
0.10
-8.45%
0.11
-7.26%
0.12
+9.86%
0.11
Current Capital Lease Obligation
0.12
-25.50%
0.16
-29.94%
0.23
+0.27%
0.23
Current Deferred Liabilities
0.04
-84.08%
0.27
-76.88%
1.17
+620.72%
0.16
Current Deferred Revenue
0.00
-100.00%
0.25
-77.52%
1.12
+1933.60%
0.06
Total Non Current Liabilities Net Minority Interest
0.90
+3.30%
0.87
-19.25%
1.08
-1.23%
1.09
Long Term Debt And Capital Lease Obligation
0.51
+33.88%
0.38
-43.74%
0.68
-27.55%
0.94
Long Term Debt
0.30
-8.60%
0.33
-26.88%
0.45
-9.33%
0.50
Long Term Capital Lease Obligation
0.21
+294.12%
0.05
-76.68%
0.23
-47.97%
0.44
Non Current Pension And Other Postretirement Benefit Plans
0.39
-11.97%
0.44
+44.29%
0.31
+95.11%
0.16
Non Current Deferred Liabilities
0.00
-100.00%
0.05
-49.95%
0.09
0.00
Non Current Deferred Revenue
0.00
-100.00%
0.05
-49.95%
0.09
0.00
Stockholders Equity
18.56
+152.94%
7.34
-41.65%
12.58
-33.38%
18.88
Common Stock Equity
18.56
+152.94%
7.34
-41.65%
12.58
-33.38%
18.88
Capital Stock
0.00
+55.14%
0.00
+67.37%
0.00
+36.33%
0.00
Common Stock
0.00
+55.14%
0.00
+67.37%
0.00
+36.33%
0.00
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
42.07
+55.07%
27.13
+67.42%
16.21
+36.38%
11.88
Ordinary Shares Number
42.07
+55.07%
27.13
+67.42%
16.21
+36.38%
11.88
Additional Paid In Capital
119.14
+34.20%
88.78
+21.43%
73.11
+27.47%
57.36
Retained Earnings
-101.36
-24.83%
-81.19
-33.58%
-60.78
-57.81%
-38.52
Gains Losses Not Affecting Retained Earnings
0.78
+413.82%
-0.25
-200.12%
0.25
+593.97%
0.04
Other Equity Adjustments
0.78
+413.82%
-0.25
-200.12%
0.25
+593.97%
0.04
Total Equity Gross Minority Interest
18.56
+152.94%
7.34
-41.65%
12.58
-33.38%
18.88
Total Capitalization
18.86
+146.02%
7.67
-41.14%
13.03
-32.76%
19.37
Working Capital
18.88
+145.54%
7.69
-40.05%
12.83
-24.38%
16.97
Invested Capital
18.97
+143.84%
7.78
-40.83%
13.15
-32.53%
19.48
Total Debt
0.73
+12.11%
0.65
-36.44%
1.03
-19.37%
1.27
Capital Lease Obligations
0.33
+54.36%
0.21
-53.32%
0.46
-31.50%
0.67
Net Tangible Assets
18.46
+156.23%
7.21
-41.82%
12.38
-33.65%
18.67
Tangible Book Value
18.46
+156.23%
7.21
-41.82%
12.38
-33.65%
18.67
Available For Sale Securities
—
—
—
1.94
Current Deferred Taxes Liabilities
0.04
+133.00%
0.02
-62.23%
0.05
-54.37%
0.11
Current Provisions
—
—
—
—
Investmentin Financial Assets
—
—
0.00
-100.00%
1.94
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-18.47
+2.16%
-18.87
-0.04%
-18.87
-28.41%
-14.69
Cash Flow From Continuing Operating Activities
-18.47
+2.16%
-18.87
-0.04%
-18.87
-28.41%
-14.69
Net Income From Continuing Operations
-20.16
+1.23%
-20.41
+8.34%
-22.27
-26.59%
-17.59
Depreciation Amortization Depletion
0.09
+11.86%
0.08
+0.59%
0.08
+30.25%
0.06
Depreciation
—
—
—
—
Depreciation And Amortization
0.09
+11.86%
0.08
+0.59%
0.08
+30.25%
0.06
Other Non Cash Items
0.80
+460.84%
0.14
+137.45%
-0.38
-85.24%
-0.21
Pension And Employee Benefit Expense
—
—
—
—
Stock Based Compensation
1.80
-24.56%
2.39
-26.66%
3.26
+113.51%
1.53
Operating Gains Losses
—
—
—
—
Gain Loss On Investment Securities
—
—
—
—
Change In Working Capital
-1.01
+6.84%
-1.08
-344.30%
0.44
-70.81%
1.51
Change In Receivables
—
—
-0.13
-3682.15%
0.00
Changes In Account Receivables
—
—
—
0.00
Change In Prepaid Assets
-0.08
+79.01%
-0.38
-952.08%
0.04
+137.91%
-0.12
Change In Payables And Accrued Expense
-0.47
-270.47%
0.27
+139.63%
-0.69
-165.03%
1.07
Change In Payable
-0.47
-270.47%
0.27
+139.63%
-0.69
-165.03%
1.07
Change In Account Payable
-0.47
-270.47%
0.27
+139.63%
-0.69
-165.03%
1.07
Change In Other Working Capital
-0.46
+53.09%
-0.98
-189.56%
1.09
+829.45%
-0.15
Change In Other Current Liabilities
—
—
-0.05
-107.11%
0.71
Investing Cash Flow
0.00
-100.00%
4.98
-51.31%
10.22
+169.19%
-14.77
Cash Flow From Continuing Investing Activities
0.00
-100.00%
4.98
-51.31%
10.22
+169.19%
-14.77
Net PPE Purchase And Sale
0.00
+100.00%
-0.02
-46.46%
-0.02
+87.09%
-0.12
Purchase Of PPE
0.00
+100.00%
-0.02
-46.46%
-0.02
+87.09%
-0.12
Capital Expenditure
—
-0.02
-46.46%
-0.02
+87.09%
-0.12
Net Investment Purchase And Sale
0.00
-100.00%
5.00
-51.16%
10.24
+169.86%
-14.66
Purchase Of Investment
—
0.00
+100.00%
-1.96
+88.97%
-17.74
Sale Of Investment
0.00
-100.00%
5.00
-59.00%
12.19
+295.99%
3.08
Financing Cash Flow
28.45
+118.63%
13.01
+2.93%
12.64
+16147.61%
-0.08
Cash Flow From Continuing Financing Activities
28.45
+118.63%
13.01
+2.93%
12.64
+16147.61%
-0.08
Net Issuance Payments Of Debt
-0.10
-6.19%
-0.09
-2.03%
-0.09
-13.07%
-0.08
Issuance Of Debt
—
—
—
—
Repayment Of Debt
-0.10
-6.19%
-0.09
-2.03%
-0.09
-13.07%
-0.08
Long Term Debt Issuance
—
—
—
—
Long Term Debt Payments
-0.10
-6.19%
-0.09
-2.03%
-0.09
-13.07%
-0.08
Net Long Term Debt Issuance
-0.10
-6.19%
-0.09
-2.03%
-0.09
-13.07%
-0.08
Net Common Stock Issuance
25.47
+92.78%
13.21
+3.79%
12.73
0.00
Proceeds From Stock Option Exercised
3.47
+1922.50%
0.17
0.00
0.00
Net Other Financing Charges
-0.40
-40.81%
-0.28
—
—
Changes In Cash
9.98
+1228.91%
-0.88
-122.12%
4.00
+113.53%
-29.55
Effect Of Exchange Rate Changes
0.47
+189.92%
-0.53
-207.94%
0.49
+2152.38%
-0.02
Beginning Cash Position
10.42
-11.93%
11.83
+61.10%
7.34
-80.11%
36.91
End Cash Position
20.87
+100.37%
10.42
-11.93%
11.83
+61.10%
7.34
Free Cash Flow
-18.47
+2.28%
-18.90
-0.08%
-18.88
-27.48%
-14.81
Income Tax Paid Supplemental Data
0.05
-44.91%
0.09
-36.05%
0.13
+4825.62%
0.00
Common Stock Issuance
25.47
+92.78%
13.21
+3.79%
12.73
0.00
Issuance Of Capital Stock
25.47
+92.78%
13.21
+3.79%
12.73
0.00
Net Preferred Stock Issuance
—
—
—
—
Preferred Stock Issuance
—
—
—
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category